Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Biotech (India) Ltd has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report was issued by Practicing Company Secretaries M/s Agrawal Kushal & Associates (UDIN: A059851H000347622). The secretarial auditor examined compliance with SEBI regulations including LODR 2015, Insider Trading Regulations 2015, Depositories Regulations, and other applicable SEBI rules. All 11 compliance areas checked — including secretarial standards, board policies, website disclosures, director disqualification checks, document preservation, performance evaluation, related party transactions, event disclosures, and prohibition of insider trading — were found compliant. No deviations were reported in Annexure A, and no additional non-compliances were noted in Annexure B. No actions were taken by SEBI or any stock exchange against the company during the review period.
This is a clean compliance report with no adverse findings, indicating the company maintained proper regulatory compliance throughout FY 2025-26. The absence of any deviations or SEBI actions is a positive signal for shareholders regarding governance standards.